• Successful $13.9m capital raise completed
• 25 FTEs reduced, delivering $6.5m in annual savings
• No impact on revenue growth or key milestones

4DMedical Limited (ASX:4DX) has announced that it has completed a strategic review of the business and will implement a series of cost reduction measures that will deliver an initial $6.5 million in annualised savings. These measures include targeted reductions in staffing and other cost-saving initiatives, ensuring the company remains financially robust and well-positioned for future success. The cost savings initiatives are expected to have no impact on 4DMedical's ability to deliver on its revenue targets or upcoming milestones, including FDA clearance of CT:VQ™ and additional contract wins. The strategic review has created opportunities to reduce the company's operating expenditure by over $6 million annually, with implementation of the cost-saving initiatives to occur immediately and expand over the course of 2025. As part of the strategic review, the company's Company Secretary and Chief Financial Officer have both left the company, with existing resources and outsourced services covering these functions. 4DMedical's Managing Director/CEO and Founder, Andreas Fouras, stated that the company's peak operating costs are now behind it, while revenue continues to grow strongly, and the current cost reduction measures are a prudent step in the current macroeconomic environment.

The company remains on track to deliver significant short-term milestones including FDA clearance of CT:VQ™ and additional contract wins.